International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 5 , Pages 1505-1511 , 1 August 2011

The Value of Botox-A in Acute Radiation Proctitis: Results From a Phase I/II Study Using a Three-Dimensional Scoring System

  • Te Vuong, M.D.

      Affiliations

    • Department of Radiation Oncology, McGill University, Montréal, Canada
    • Corresponding Author InformationReprint requests to: Te Vuong, Radiation Oncology Department, SMBD Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Montréal, Québec H3T 1E2, Canada. Tel: (514) 340-8222, ext: 2073; Fax: (514) 340-7548
    • ,
  • Kevin Waschke, M.D.

      Affiliations

    • Department of Gastroenterology, McGill University, Montréal, Canada
    • ,
  • Tamim Niazi, M.D.

      Affiliations

    • Department of Radiation Oncology, McGill University, Montréal, Canada
    • ,
  • Carole Richard, M.D.

      Affiliations

    • Department of Colorectal Surgery, Université de Montréal, Montréal, Canada
    • ,
  • Josee Parent, M.D.

      Affiliations

    • Department of Gastroenterology, McGill University, Montréal, Canada
    • ,
  • Sender Liberman, M.D.

      Affiliations

    • Department of Colorectal Surgery, McGill University, Montréal, Canada
    • ,
  • Serge Mayrand, M.D.

      Affiliations

    • Department of Radiation Oncology, McGill University, Montréal, Canada
    • ,
  • Rasmy Loungnarath, M.D.

      Affiliations

    • Department of Colorectal Surgery, Université de Montréal, Montréal, Canada
    • ,
  • Barry Stein, M.D.

      Affiliations

    • Department of Colorectal Surgery, McGill University, Montréal, Canada
    • ,
  • Slobodan Devic, Ph.D.

      Affiliations

    • Department of Medical Physics, McGill University, Montréal, Canada

Received 16 November 2009 ,Revised 30 March 2010 ,Accepted 2 April 2010.

References 

  1. Buchi K. Radiation proctitis: therapy and prognosis. JAMA. 1991;265(9):1180
  2. Nussbaum ML, Campana TJ, Weese JL. Radiation-induced intestinal injury. Clin Plast Surg. 1993;20(3):573–580
  3. Babb RR. Radiation proctitis: A review. Am J Gastroenterol. 1996;91(7):1309–1311
  4. Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48(4):1111–1117
  5. Goldner G, Tomicek B, Becker G, et al. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: Results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys. 2007;67(1):78–83
  6. Venerito M, Mönkemüller K, Rickes S, et al. Education and imaging. Gastrointestinal: radiation proctitis. J Gastroenterol Hepatol. 2007;22(5):761
  7. Alert J, Jimenez J, Beldarraín L, et al. Complications from irradiation of carcinoma of the uterine cervix. Acta Radiol Oncol. 1980;19(1):13–15
  8. Kneebone A, Mameghan H, Bolin T, et al. The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: A double blind, randomized trial. Int J Radiat Oncol Biol Phys. 2001;51(3):628–635
  9. Simone NL, Ménard C, Soule BP, et al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by EPIC score. Int J Radiat Oncol Biol Phys. 2008;70(1):90–95
  10. Greven KM, Lanciano RM, Herbert SH, et al. Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation. Int J Radiat Oncol Biol Phys. 1991;21(4):919–923
  11. Zimmermann FB, Feldmann HJ. Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. Strahlenther Onkol. 1998;174(Suppl 3):85–89
  12. Hovdenak N, Sorbye H, Dahl O. Sucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clin Oncol (R Coll Radiol). 2005;17(6):485–491
  13. Venkitaraman R, Price A, Coffey J, et al. Pentoxifylline to treat radiation proctitis: A small and inconclusive randomised trial. Clin Oncol (R Coll Radiol). 2008;20(4):288–292
  14. Spencer CM, McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs. 1995;50(5):854–872
  15. O'Brien PC, Franklin Cl, Dear KBG, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother Oncol. 1997;45(2):117–123
  16. Lucidarme D, Marteau P, Foucault M, et al. Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis. Aliment Pharmacol Ther. 1997;11(2):335–340
  17. Ben-Josef E, Han S, Tobi M, et al. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. Int J Radiat Oncol Biol Phys. 2002;53(5):1160–1164
  18. Singh AK, Ménard C, Guion P, et al. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: A pilot study. Int J Radiat Oncol Biol Phys. 2006;65(4):1008–1013
  19. Kouloulias VE, Kouvaris JR, Pissakas G, et al. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. Strahlenther Onkol. 2004;180(9):557–562
  20. Kouvaris J, Kouloulias V, Malas V, et al. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol. 2003;179(3):167–174
  21. Vernia P, Fracasso PL, Casale V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet. 2000;356(9237):1232–1235
  22. Vuong T, Belliveau PJ, Michel RP, et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: Early results of a phase I/II study. Dis Colon Rectum. 2002;45(11):1486–1493
  23. Vuong T, Devic S, Moftah B, et al. High-dose-rate endorectal brachytherapy in the treatment of locally advanced rectal carcinoma: Technical aspects. Brachytherapy. 2005;4(3):230–235
  24. Vuong T, Devic S, Podgorsak EB. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin Oncol. 2007;19:701–705
  25. Vuong T, Richard C, Faria S, et al. Clinical applications of high dose rate endorectal brachytherapy (HRDEBT) in the multimodality treatment of patients with rectal cancer. Ann Oncol. 2008;19(Suppl 1):124
  26. Tsui JKC, Stoessl AJ, Eisen A, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2(8501):245–247
  27. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994;59(1):65–69
  28. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine. 1998;23(15):1662–1666
  29. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000;85(1-2):101–105
  30. Foster L, Clapp L, Erickson M, et al. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology. 2001;56(10):1290–1293
  31. Pasricha PJ, Ravich WJ, Hendrik TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 1995;332(12):774–778
  32. Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut. 2000;46(5):597–600
  33. Zaninotto G, Vergadoro V, Annese V, et al. Botulinum toxin injection versus laparoscopic myotomy for the treatment of esophageal achalasia: Economic analysis of a randomized trial. Surg Endosc. 2004;18(4):691–695
  34. Brisinda G, Maria G, Bentivoglio AR, et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 1999;341(2):65–69
  35. Lindsey I, Cunningham C, Jones OM, et al. Fissurectomy-botulinum toxin: A novel sphincter-sparing procedure for medically resistant chronic anal fissure. Dis Colon Rectum. 2004;47(11):1947–1952
  36. Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol. 2004;46(6):784–791
  37. Zermann D, Ishigooka M, Schubert J, et al. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain?. Eur Urol. 2000;38(4):393–399
  38. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur Urol. 2003;44(2):165–174
  39. Hallett M. How does botulinum toxin work?. Ann Neurol. 2000;48(1):7–8
  40. Van Putten MJ, Padberg M, Tavy DL. In vivo analysis of end-plate noise of human extensor digitorum brevis muscle after intramuscularly injected botulinum toxin type A. Muscle Nerve. 2002;26(6):784–790
  41. Gomez-Ramirez AM, Villegas-Pérez MP, de Imperial JM, et al. Effects of intramuscular injection of botulinum toxin and doxorubicin on the survival of abducens motoneurons. Invest Ophthalmol Vis Sci. 1999;40(2):414–424
  42. Jones CA, Nyberg L. Epidemiology of interstitial cystitis. Urology. 1997;49(Suppl 5A):2–9
  43. Klutke CG, Klutke JJ. Interstitial cystitis/painful bladder syndrome for the primary care physician. Can J Urol. 2008;15(Suppl 1):44–52
  44. Mishell DR, Dell J, Sand PK. Evolving trends in the successful management of interstitial cystitis/painful bladder syndrome. J Reprod Med. 2008;53(9):651–656
  45. Hanno P, Nordling J, van Ophoven A. What is new in bladder pain syndrome/interstitial cystitis?. Curr Opin Urol. 2008;18(4):353–358
  46. Seth A, Teichman JM. What's new in the diagnosis and management of painful bladder syndrome/interstitial cystitis?. Curr Urol Rep. 2008;9(5):349–357
  47. Steers WD, Tuttle JB. Neurogenic inflammation and nerve growth factor: possible roles in interstitial cystitis. In: Sant GR, ed. Interstitial Cystitis. Philadelphia, PA: Lippincott-Raven; 1997:67–75.
  48. Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–875
  49. De Micheli C, Fornengo P, Bosio A, et al. Severe radiation-induced proctitis treated with botulinum anatoxin type A. J Clin Oncol. 2003;21(13):2627
  50. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107(1-2):125–133
  51. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43(Suppl 1):S9–S15

 Conflict of interest: none.

PII: S0360-3016(10)00590-0

doi: 10.1016/j.ijrobp.2010.04.017

International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 5 , Pages 1505-1511 , 1 August 2011

Article Tools

* Image Usage & Resolution